MMP9 and fragile X syndrome: Despites this, measurement of MMP9 proteolytic activity remains one of the promising biomarkers of FXS, as shown by the fact that the MMP9 dysregulation monitored in KO mice and post-mortem patient brains is replicated in FXS blood.